Join the Opdivo group to help and get support from people like you.
Opdivo News
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
FRIDAY, July 18, 2025 – Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV resectable melanoma,...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 – The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health...
Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment
WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer. Unfortunately, that hope doesn’t extend to people without health ins...
Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival
TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says. Corticosteroids are commonly prescribed ...
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
THURSDAY, June 12, 2025 – For patients with metastatic melanoma, mitochondrial (MT) haplogroup T (HG-T) is associated with resistance to an anti-programmed cell death protein-1-based immune...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 – Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients, according to a study...
Immune Therapy Works As Well In Senior Cancer Patients As In Younger Adults
TUESDAY, April 22, 2025 — It’s well-known that a person’s immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn’t appear t...
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
TUESDAY, April 22, 2025 – Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICIs) for...
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
MONDAY, April 21, 2025 — Immunotherapy might help keep lung cancer at bay for months or even years after the treatment has been abandoned due to side effects, a new study says. Immune checkpoint i...
FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer
TUESDAY, April 15, 2025 – The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic...
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 11, 2025 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (...
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Apr 08, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (i...
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers
FRIDAY, Feb. 7, 2025 – Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a new phase 3 trial finds. The study involved patients with...
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
THURSDAY, Feb. 6, 2025 – For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding...
Further information
Related condition support groups
Colorectal Cancer, Hepatocellular Carcinoma, Gastric Cancer, Hodgkin's Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma